Found 50 matching trials
A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)
PHASE3This is a prospective open-label, uncontrolled, single-blind, pilot clinica...
Location
University of Alberta
Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention
PHASE2To examine the prevalence of humoral immunodeficiency in patients with Chro...
Location
Rochester Regional Health Ctr for Clinical Research - Alexander Park
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)
PHASE3The objective of this study is to assess the efficacy, safety, tolerability...
Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
PHASE2The purpose of this study is to determine whether Hizentra is a safe and ef...
Location
Phoenix Neurological Associates
Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
PHASE4This multicenter, open-label, parallel-arm, non-randomized study is designe...
Location
Clinical Research Center of Alabama
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy
PHASE3The objective of this study is to assess the efficacy, tolerability, safety...
IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3
PHASE2The objective of this study is to develop a rationale for the selective tre...
Location
Beth Israel Deaconness Medical Center
At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill
N/AThe main aim of this study is to determine the impact of digital health tec...
Location
Research Triangle Park
Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig
PHASE2Patients with chronic lymphocytic leukemia (CLL) are at increased risk of i...
Location
Allergy, Immunology, Rheumatology at Rochester Regional Health
Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
PHASE3This is a prospective, phase 3, multicenter, double-blind, randomized place...
Location
University of Alabama Hospital at Birmingham